New Delhi, June 9 :Washington DC-based Advanced Medical Technology Association which represents US pharma and tech majors have alleged that Prime Minister Narendra Modi’s ‘ Make in India’ programme is a move towards protectionism.
The world’s largest association of medical device companies, Advanced Medical Technology Association (AdvaMed)presented its report to Commerce Secretary Wilbur Ross and US Trade Representative Robert Lighthizer in 2017, in which it conveyed that the “Make in India” scheme has been used by parts of the Indian government to justify protectionist measures”, the Indian Expres report stated.
President Donald Trump has slammed India’s trade barriers in the past citing tariff imposed by India on Harley-Davidson motorcycles as an example of “unfair” trade practices that the United States must fight with “reciprocal taxes”, while Indian firms export “thousands and thousands of motorcycles” to the U.S. for free. Since America does not have a levy on Indian motorcycle imports.
But he’s also been trying to boost domestic manufacturing with his “Make in India” campaign.
After Indian government has imposed price caps on stents and artificial knee implants AdvaMed stated that “in addition to price controls as a barrier, the regulatory environment in India continues to be opaque and unpredictable”.
Capping the price of stents in India will adversely effect the innovations and limit access to the world -class medical care. Another significant aspect is that the price caps could deter companies from selling the latest, mostly imported technology and lowering the price does not amounts to fall in the medical expenses as the hospitals could increase “incidental expenses”.
Commerce Secretary Wilbur Ross said that the US will not sit back and watch as the domestic businesses are getting destroyed by unfair foreign government subsidies and dumping.America recently decided to impose anti-dumping duties on the stainless steel flanges imported from China and India.